Fig. 3From: Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trialsForest plots of ORR by RECIST 1.1 (A), ORR by mRECIST (B), DCR by RECIST 1.1 (C) and DCR by mRECIST (D)Back to article page